Upcoming Events

Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting

Jun 8 – Jun 11, 2024

View All Events

Latest Financial Results

FY 2023

Fiscal Year Ended Dec 31, 2023

Latest 10-K

View Latest 10-K
Nasdaq Photo
Email Alerts

Stay informed and receive company updates straight to your inbox

Stock Information

Company Overview

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; Phase 1-stage MNPR-101 for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics Radiopharma Presentation

Monopar Therapeutics Radiopharma Presentation

Download Monopar Therapeutics Radiopharma Presentation


Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization.

Investor Contact Information


Monopar Therapeutics Inc.
1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091
T: (847) 388-0349